Online inquiry

IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6716MR)

This product GTTS-WQ6716MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6716MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3718MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ7525MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ4263MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ13831MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ7032MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Fab C225
GTTS-WQ12336MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ1020MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ8590MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW